Individualized Treatments in Adults With Relapsed/Refractory Cancers

Launched by CASE COMPREHENSIVE CANCER CENTER · Sep 1, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring a personalized approach to treat adults with certain types of cancer that haven't responded to previous treatments or have come back after treatment. The goal is to find tailored therapies that can work better for patients who have few options left. This study welcomes participants aged 18 and older, regardless of gender, race, or ethnicity, who have been diagnosed with recurrent or refractory cancer and have already tried at least two different treatments without success. Participants should also have available tissue samples from their tumors for testing.

If you choose to participate, you’ll undergo some tests, including a biopsy or blood draw, to help researchers understand your cancer better and develop a more effective treatment plan for you. The trial is currently recruiting participants, so you could help advance cancer research while also exploring new treatment possibilities tailored to your specific needs. It's important to know that this study is designed for patients whose cancer has limited treatment options, and it cannot accept those who have newly diagnosed cancers or those that can be cured with standard therapies.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants aged 18 years or older at the time of enrollment on this study of any gender, race, or ethnicity.
• • Patients with suspected or confirmed diagnosis of recurrent or refractory cancer with no curative treatment options.
• • Participants who have undergone at least two lines of previous therapy.
• • Participants who are scheduled for or have recently had biopsy or tumor excised (solid tumors) or bone marrow aspirate (blood cancers) or who have scheduled or recently had paracentesis or thoracentesis performed.
• • Participants willing to have a blood draw or buccal swab done for the purposes of genetic testing.
• • Participants willing to sign informed consent.
• Exclusion Criteria:
• • Participants who do not have malignant tissue available and accessible.
• • Participants for whom the amount of excised malignant tissue is not sufficient for the ex vivo drug testing and/or genetic profiling.
• • Participants with newly diagnosed tumors and tumors that have high (\>90%) cure rate with safe standard therapy.